Mycophenolate Mofetil Initiation in Renal Transplant Patients at Different Times Posttransplantation: the TranCept Switch Study
dc.contributor.author | Meier-Kriesche, Herwig-Ulf | |
dc.contributor.author | Merville, Pierre | |
dc.contributor.author | Tedesco-Silva, Helio [UNIFESP] | |
dc.contributor.author | Heemann, Uwe | |
dc.contributor.author | Kes, Petar | |
dc.contributor.author | Haller, Hermann | |
dc.contributor.author | Rostaing, Lionel | |
dc.contributor.author | Gafner, Nesrin | |
dc.contributor.author | Bernasconi, Corrado | |
dc.contributor.institution | Univ Florida | |
dc.contributor.institution | Hop Pellegrin | |
dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor.institution | Tech Univ Munich | |
dc.contributor.institution | Univ Hosp Ctr Zagreb | |
dc.contributor.institution | Hannover Med Sch | |
dc.contributor.institution | CHU Rangueil | |
dc.contributor.institution | Nesrin Gafner Consulting | |
dc.contributor.institution | F Hoffmann La Roche & Co Ltd | |
dc.date.accessioned | 2016-01-24T14:16:46Z | |
dc.date.available | 2016-01-24T14:16:46Z | |
dc.date.issued | 2011-05-15 | |
dc.description.abstract | Background. Despite evidence of favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, its introduction at different times posttransplant has not been studied in large cohorts.Methods. Single-organ renal allograft recipients (n=2217) who had MMF introduced 6 months to more than 20 years posttransplantation for various reasons were included in TranCept Switch, a multicenter, noninterventional, observational 4-year study. Changes in renal function before and after the introduction of MMF were analyzed.Results. MMF was introduced because of renal function decline in 43% of patients and poor tolerability with previous treatment in 23% of patients. the change in slope of the calculated glomerular filtration rate (modification of diet in renal diseases formula) regression line before and after MMF initiation was +2.01 mL/min per year (P<0.001) on average. the greatest benefit was noted in patients who received MMF because of renal function decline and in whom calcineurin inhibitor treatment was subsequently reduced or withdrawn (+3.09 mL/min per year). Time from transplantation to MMF introduction influenced the glomerular filtration rate at MMF initiation (slow progressive deterioration) but not the direction of the slope change, which was positive even for late introduction.Conclusion. MMF introduction may be associated with improvement or stabilization of renal function even several years after transplantation. | en |
dc.description.affiliation | Univ Florida, Coll Med, Div Nephrol, Gainesville, FL 32610 USA | |
dc.description.affiliation | Hop Pellegrin, Serv Nephrol Transplantat Dialyse, F-33076 Bordeaux, France | |
dc.description.affiliation | Universidade Federal de São Paulo, Hosp Rim & Hipertensao, São Paulo, Brazil | |
dc.description.affiliation | Tech Univ Munich, Klinikum Rechts Isar, Chirurg Klin, D-8000 Munich, Germany | |
dc.description.affiliation | Univ Hosp Ctr Zagreb, Dept Internal Med, Zagreb, Croatia | |
dc.description.affiliation | Hannover Med Sch, Nephrol Abt, D-30623 Hannover, Germany | |
dc.description.affiliation | CHU Rangueil, Dept Nephrol Dialysis & Organ Transplantat, F-31054 Toulouse, France | |
dc.description.affiliation | Nesrin Gafner Consulting, Biel, Switzerland | |
dc.description.affiliation | F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland | |
dc.description.affiliationUnifesp | Universidade Federal de São Paulo, Hosp Rim & Hipertensao, São Paulo, Brazil | |
dc.description.source | Web of Science | |
dc.description.sponsorship | F. Hoffmann-La Roche Ltd. | |
dc.description.sponsorship | Basel, Switzerland | |
dc.description.sponsorship | Bristol Meyer Squibb | |
dc.description.sponsorship | Gilead | |
dc.description.sponsorship | Life cycle Pharma | |
dc.description.sponsorship | Novartis | |
dc.description.sponsorship | Pfizer | |
dc.description.sponsorship | Astellas | |
dc.description.sponsorship | Forest | |
dc.description.sponsorship | Jansen-Cilag | |
dc.format.extent | 984-990 | |
dc.identifier | http://dx.doi.org/10.1097/TP.0b013e3182130966 | |
dc.identifier.citation | Transplantation. Philadelphia: Lippincott Williams & Wilkins, v. 91, n. 9, p. 984-990, 2011. | |
dc.identifier.doi | 10.1097/TP.0b013e3182130966 | |
dc.identifier.issn | 0041-1337 | |
dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/33707 | |
dc.identifier.wos | WOS:000289773000011 | |
dc.language.iso | eng | |
dc.publisher | Lippincott Williams & Wilkins | |
dc.relation.ispartof | Transplantation | |
dc.rights | Acesso restrito | |
dc.subject | Mycophenolate mofetil | en |
dc.subject | Calcineurin inhibitor withdrawal | en |
dc.subject | Glomerular filtration rate | en |
dc.subject | Nephrotoxicity | en |
dc.title | Mycophenolate Mofetil Initiation in Renal Transplant Patients at Different Times Posttransplantation: the TranCept Switch Study | en |
dc.type | Artigo |